New Partnership Will Put Digital Health and New Drug Companies Front and Center

Oxford University, Sensyne Health, a leader in artificial intelligence, and Germany-based Evotec teamed together to create several spinout firms with the goal of accelerating data-driven medication discovery and development.The three organizations will provide funding for the LAB10x model, a new BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) model that will promote research at Oxford University in the many domains of clinical artificial intelligence and digital health. The use of cutting-edge digital solutions and clinical AI algorithms in the programs for digital health research and development forms the foundation of the strategy. The renowned university Oxford University Innovation entity will source the digital health initiatives, per the conditions of the agreement. The AI specialists at Sensyne, a UK-based company, will support that research.